Drilldown: Medicines

Nav

Choose a table:

Medicines (732)

Medicines > routes

: insufflated

or intramuscular

Use the filters below to narrow your results.

2C-B (1) · Hydroxyzine (hydrochloride; pamoate salt) (1) · Lorazepam (1) · Methocarbamol (1) · Methotrexate (1) · Morphine (sulfate) (1) · Phencyclidine (1) · Progesterone (micronized) (1) · Triamcinolone (acetonide and other esters) (1)

Ativan (oral, injectable), Loreev XR (1) · Kenalog (injectable), Nasacort (intranasal), Aristocort (topical), Trianex (1) · MS Contin (ER), Kadian (ER), Avinza (ER), Roxanol (IR oral solution), Duramorph (epidural / IT), Astramorph (IV), Infumorph (intrathecal pump), MorphaBond (IR abuse-deterrent) (1) · Nexus, Eroxan (historical, late-1980s through mid-1990s) (1) · Prometrium (oral), Endometrin (vaginal), Crinone (vaginal gel), Prochieve (1) · Robaxin (oral, injectable) (1) · Sernyl (human, withdrawn 1965); Sernylan (veterinary, withdrawn 1978) (1) · Trexall, Otrexup, Rasuvo, Xatmep, Rheumatrex (discontinued) (1) · Vistaril (pamoate), Atarax (HCl, discontinued in US as brand) (1)

None (7) · 5-HT2A partial agonist (1) · '"`UNIQ--vote-0000001D-QINU`"' '''QT prolongation''' risk at high doses prompted the FDA's 2015 caution against use in patients with prolonged QT or with concurrent QT-prolonging medicines'"`UNIQ--ref-0000001E-QINU`"'. (1)

None (1) · Anxiety: 0.5-1 mg PO BID-TID. Insomnia: 1-2 mg PO at bedtime. Status epilepticus: 4 mg IV (adult), repeat after 5-10 minutes if needed. Acute agitation: 1-2 mg IM (1) · Anxiety: 25-50 mg PO QID. Pruritus: 25 mg PO TID-QID. Insomnia: 25-50 mg PO at bedtime. Pediatric: 50-100 mg/day divided (1) · HRT cyclic: 200 mg PO HS days 1-12 of each month; continuous: 100 mg PO daily; ART luteal support 100 mg vaginal TID or 90 mg gel daily (1) · IR oral: 15-30 mg every 4 hours as needed. ER opioid-naive: 15-30 mg every 12 hours. IV/IM/SC: 2-10 mg every 3-4 hours. Epidural / intrathecal: see surgical or palliative-care protocols (1) · No current medical indication. Historical anesthetic dose 0.25 mg/kg IV (Sernyl). (1) · Oral: 1500 mg PO QID for 2-3 days (load), then 750-1500 mg QID maintenance. IV/IM: 1000 mg every 8 hours for acute spasm (1) · Rheumatologic: 7.5-15 mg PO or SC '''once weekly''' (not daily — daily dosing is a recognized fatal error); folic acid 1 mg PO daily on non-MTX days; oncology dosing is far higher and indication-specific (1) · Topical 0.025-0.5% cream/ointment BID; intra-articular 5-40 mg per joint q3-6 months; intranasal Nasacort 110 mcg/spray, 2 sprays/nostril daily; oral paste 0.1% to lesion 2-3×/d (1)

None (1) · 2.5 mg tablets; 10-50 mg/mL injection; pre-filled subcutaneous autoinjectors (Otrexup, Rasuvo); 2.5 mg/mL oral solution (Xatmep) (1) · Historical: Sernyl 25 mg tablets, 10 mg/mL injection (human); Sernylan 100 mg/mL injection (veterinary). Illicit: white crystalline powder, oily liquid, "dipped" cigarettes ("wet"), tablets. (1) · IR tablets 15, 30 mg; oral solution 10 mg/5 mL, 20 mg/mL, 100 mg/5 mL (concentrated); suppositories; ER tablets and capsules in multiple strengths; injectable 0.5-50 mg/mL (1) · Oral 100, 200 mg capsules (peanut oil; check allergy); 100 mg vaginal insert (Endometrin); 4%, 8% vaginal gel (Crinone); IM 50 mg/mL (1) · Tablets 0.5, 1, 2 mg; oral concentrate 2 mg/mL; injection 2 mg/mL and 4 mg/mL; Loreev XR capsules 1, 2, 3 mg (1) · Tablets 10, 25, 50 mg (HCl); capsules 25, 50, 100 mg (pamoate); oral suspension 25 mg/5 mL; injection 25, 50 mg/mL (IM only, never IV) (1) · Tablets 500, 750 mg; injection 100 mg/mL (1) · Topical creams, ointments, lotions, dental paste (0.025-0.5%); Kenalog 10 mg/mL, 40 mg/mL injection; Nasacort 55 mcg/spray intranasal; oral inhaler discontinued in US (1)

None (1) · 10 mg/day (anxiety, oral) (1) · 400 mg/day theoretical; in practice rarely exceeds 200 mg/day (1) · 8 g/day (oral, short-term load); 6 g/day (chronic) (1) · Indication-dependent; 200-400 mg/d oral typical (1) · Indication-specific (1) · N/A (no current medical indication) (1) · No fixed ceiling; titrate to clinical effect and tolerability with CDC opioid prescribing guidance constraints on morphine-milligram-equivalent (MME) totals (1) · Rheumatologic ~25 mg/week; oncology indication-specific (1)

15-30 minutes (oral) (1) · 30-60 minutes (oral); 5 minutes (IV); 15-30 minutes (IM) (1) · 45-75 min (oral) (1) · 5-10 minutes (IV); 30 minutes (oral IR); slower for ER and rectal (1) · Rheumatologic effect at 4-8 weeks; ectopic resolution over 2-3 weeks (1) · Sedation/dizziness within hours of oral dose; endometrial effects over days (1) · Smoked 2-5 min; insufflated 5-15 min; oral 30-60 min; IV / IM ~5-15 min (1) · Topical hours; intra-articular days to weeks (1) · ~30 minutes (oral) (1)

3-5 hours (IR); 8-24 hours (ER); 12-24 hours (epidural / intrathecal) (1) · 4-6 hours (2) · 4-8 h (1) · 4-8 hours typical; longer at high doses; residual cognitive and perceptual effects up to 48 hours (1) · 6-8 hours (1) · Intra-articular 3-6 months (depot effect of acetonide microcrystals) (1) · Once-weekly dosing in rheumatology (1) · Oral: 8-12 hours; vaginal: 24+ hours; IM: days (1)

1-2 hours'"`UNIQ--ref-00000017-QINU`"' (1) · 12-15 hours (intermediate); '''no active metabolites''' (key clinical feature)'"`UNIQ--ref-00000023-QINU`"' (1) · 14-25 hours (longer in elderly and hepatic impairment)'"`UNIQ--ref-00000026-QINU`"' (1) · 3-10 hours (low dose); 8-15 hours (high dose); much longer in third-space accumulation (pleural effusion, ascites)'"`UNIQ--ref-000007C8-QINU`"' (1) · Highly variable, 7-46 hours (mean ~21 h); lipophilic deposition in fat with delayed re-release contributes to wide range'"`UNIQ--ref-00000065-QINU`"' (1) · Morphine 2-4 hours; morphine-6-glucuronide active metabolite 2-4 hours (longer with renal impairment)'"`UNIQ--ref-00000020-QINU`"' (1) · Not well characterized (1) · Plasma ~3-5 hours; biologic effect substantially longer (~12-36 hours for intermediate-acting glucocorticoids)'"`UNIQ--ref-00000666-QINU`"' (1) · ~5-20 hours (oral micronized; highly variable)'"`UNIQ--ref-00000726-QINU`"' (1)

60-70% PO at low doses; saturable at high doses (parenteral routes preferred above 15-25 mg/week)'"`UNIQ--ref-000007C9-QINU`"' (1) · Not well characterized (1) · Oral: very low (extensive first-pass); micronization improves uptake somewhat. Vaginal: high local effect with lower systemic levels (first-uterine-pass concentration)'"`UNIQ--ref-00000727-QINU`"' (1) · Topical/intranasal: high local, low systemic; intra-articular: local depot then systemic absorption'"`UNIQ--ref-00000667-QINU`"' (1) · ~100% (oral; near-complete absorption)'"`UNIQ--ref-00000018-QINU`"' (1) · ~25-40% (oral; extensive first-pass)'"`UNIQ--ref-00000021-QINU`"' (1) · ~72% oral; ~85% smoked'"`UNIQ--ref-00000066-QINU`"' (1) · ~80% (oral)'"`UNIQ--ref-00000027-QINU`"' (1) · ~90% (oral)'"`UNIQ--ref-00000024-QINU`"' (1)

None (2) · '''Contraindicated in pregnancy''' (Category X); abortifacient and teratogenic. Discontinuation 3-6 months before conception is standard.[[[Pharmacopedia:Citation needed|citation needed]]] (1) · Chronic third-trimester exposure produces neonatal opioid withdrawal syndrome and respiratory depression at delivery.[[[Pharmacopedia:Citation needed|citation needed]]] (1) · Limited human data.[[[Pharmacopedia:Citation needed|citation needed]]] (1) · Limited human data; older agent with substantial use experience; some signal for first-trimester exposure but not conclusive.[[[Pharmacopedia:Citation needed|citation needed]]] (1) · Not established (1) · Some signal for cleft lip/palate with first-trimester exposure (debated); neonatal sedation and withdrawal with third-trimester exposure.[[[Pharmacopedia:Citation needed|citation needed]]] (1) · Topical/intranasal generally low-risk; intra-articular and high-dose injection: weigh risk individually.[[[Pharmacopedia:Citation needed|citation needed]]] (1)

OTC (lowest-strength topicals) and [[USLegal:Prescription only|Rx-only]] (higher strengths, injectable) in US (1) · [[USLegal:DEA Schedule II|Schedule II]] controlled substance in US (rescheduled from Schedule III in 1978). No accepted medical use. UN Convention on Psychotropic Substances Schedule II internationally.'"`UNIQ--ref-00000067-QINU`"' (1) · [[USLegal:DEA Schedule I|Schedule I]] (United States) (1) · [[USLegal:Prescription only|Rx-only]] in US (2) · [[USLegal:Prescription only|Rx-only]] in US. Not a controlled substance, distinguishing it from carisoprodol which is Schedule IV'"`UNIQ--ref-00000019-QINU`"' (1) · [[USLegal:Prescription only|Rx-only]] in US. Not a controlled substance, which is a meaningful clinical advantage over the benzodiazepine alternatives for short-term anxiety'"`UNIQ--ref-00000028-QINU`"' (1) · [[USLegal:Schedule II|Schedule II controlled substance]] in US; WHO essential medicine'"`UNIQ--ref-00000022-QINU`"' (1) · [[USLegal:Schedule IV|Schedule IV controlled substance]] in US. Carries the benzodiazepine class '''Boxed Warning''' for risk of fatal respiratory depression, coma, and death when combined with opioids'"`UNIQ--ref-00000025-QINU`"' (1)

Showing below up to 9 results in range #1 to #9.

M

P

T

Triamcinolone